FDA Shortens Monitoring Time for Amgen's Imdelltra in Lung Cancer Treatment
Amgen's Imdelltra has been updated by the FDA to reduce the initial monitoring time for patients with extensive-stage small cell lung cancer. The revised prescribing information cuts post-infusion observation from 22-24 hours to six, eight hours for the first two doses, replacing the earlier requirement of 22 to 24 hours of observation. This change aims to simplify care and help address practical barriers associated with administering Imdelltra.
The updated label still recommends patients remain within one hour of suitable medical facilities for 48 hours from the start of the first and eighth day infusions, accompanied by a caregiver. Amgen believes this regulatory update could reduce the time patients need to spend in healthcare settings during the early stages of treatment.